Motorix (domperidone) coated tablets 0.01 g. №30

$13.00

Purpose: Enhances motility in gastrointestinal tract; treats nausea, vomiting, and delayed gastric emptying.

SKU: MED59824 Category:

Description

Motorix (domperidone) Coated Tablets 0.01 g. №30

Ingredients

Active ingredient: Domperidone 0.01 g per tablet.

Dosage

Recommended dosage: The usual dose is 1-2 tablets taken 3-4 times a day before meals. Do not exceed the maximum daily dose of 8 tablets.

Indications

Motorix tablets are indicated for the relief of symptoms of nausea and vomiting.

Contraindications

Do not use Motorix tablets if you have a known hypersensitivity to domperidone or any of the excipients. Consult your healthcare provider before use.

Directions

Swallow the tablets whole with a glass of water. Do not crush or chew the tablets. Take as directed by your healthcare provider.

Scientific Evidence

Domperidone, the active ingredient in Motorix tablets, exerts its antiemetic effect by blocking dopamine receptors in the chemoreceptor trigger zone of the brain. Studies have shown that domperidone is effective in the treatment of nausea and vomiting, particularly in conditions such as gastroenteritis and chemotherapy-induced nausea.

Additional Information

Motorix tablets have been widely used in clinical practice for the management of gastrointestinal motility disorders. It is important to follow the recommended dosage and not exceed the maximum daily dose to avoid potential side effects. If symptoms persist, consult a healthcare professional for further evaluation.

Pharmacological Effects: Domperidone acts as a dopamine antagonist, which results in increased gastrointestinal motility and decreased nausea and vomiting. It does not readily cross the blood-brain barrier, reducing the risk of central side effects.

Clinical Trials: Clinical trials have demonstrated the efficacy of domperidone in the treatment of nausea and vomiting. A study by Khanna et al. (2018) showed that domperidone was superior to placebo in reducing the frequency and severity of nausea in patients with functional dyspepsia.